Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$79.81 USD
-0.73 (-0.91%)
Updated Jun 20, 2024 04:00 PM ET
After-Market: $79.77 -0.04 (-0.05%) 6:10 PM ET
2-Buy of 5 2
C Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.81 USD
-0.73 (-0.91%)
Updated Jun 20, 2024 04:00 PM ET
After-Market: $79.77 -0.04 (-0.05%) 6:10 PM ET
2-Buy of 5 2
C Value F Growth D Momentum F VGM
Zacks News
Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up
by Zacks Equity Research
Merrimack (MACK) reported narrower-than-expected loss in the third quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.
Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates
by Zacks Equity Research
Pacira's (PCRX) earnings surpassed estimates but sales missed the same in the third quarter of 2017. The company remains focused on the label expansion of Exparel.
Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Catalyst Pharma (CPRX) remains focused on the development of its pipeline candidate firdapse in the third quarter of 2017.
Mallinckrodt (MNK) Earnings, Sales Decline Y/Y in Q3
by Zacks Equity Research
Mallinckrodt (MNK) sales and earnings declined in the third-quarter due to volume Acthar declines.
Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag
by Zacks Equity Research
Agenus (AGEN) incurred in line loss but sales missed estimates in the third quarter of 2017.
Keryx (KERX) Q3 Loss Wider Than Expected, Stock Declines
by Zacks Equity Research
Keryx (KERX) posted wider-than-expected loss in the third quarter of 2017. The company also received approval for label expansion of its lead drug Auryxia.
Alnylam's (ALNY) Q3 Earnings, Revenues Miss Estimates
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) incurred wider than expected loss and missed sales estimates in the third quarter of 2017.
Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reports another quarter of lackluster Belviq sales. However, the company is likely to advance ralinepag in phase III study based on positive data from the previous stage.
Prothena (PRTA) Earnings Beat in Q3, Pipeline in Focus
by Zacks Equity Research
Prothena (PRTA) reported a narrower-than-expected loss in the third quarter as the company continued with its pipeline progress.
Key Predictions for Q3 Earnings Reports of PBYI, XON, LGND
by Zacks Equity Research
The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if some small biotechs, due to report on Nov 9, follow suit.
Endocyte (ECYT) Posts Narrower-than-Expected Q3 Loss
by Zacks Equity Research
Endocyte (ECYT) posted narrower-than-expected loss in the third quarter of 2017. The company will focus on the development of PSMA-617 that it licensed in the same quarter.
What's in Store for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology that helps it form partnerships with several leading healthcare companies might drive the stock in Q3.
ImmunoGen (IMGN) Q3 Loss Wider Than Expected, Cash View Up
by Zacks Equity Research
ImmunoGen (IMGN) reports wider-than-expected loss in Q3. Revenues also lag expectations considerably.
Corcept (CORT) Q3 Earnings Miss Estimates, Guidance Raised
by Zacks Equity Research
Corcept Therapeutics' (CORT) earnings miss but sales beat expectations in the third quarter of 2017. The company remains focused on advancing its cortisol modulation platform.
PDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings top estimates in Q3. Revenues also grow year over owing to rise in royalty rights.
AMAG Pharma's (AMAG) Q3 Earnings Beat, Lowers '17 Outlook
by Zacks Equity Research
AMAG Pharmaceuticals' (AMAG) earnings surpassed estimates but missed revenues in the third quarter of 2017.
Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 10.3% in Session
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Agios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y
by Zacks Equity Research
Agios (AGIO) reports narrower-than-expected loss with revenues marginally beating estimates. The top line also improves year over year, thanks to reimbursement received from Celgene.
Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q3
by Zacks Equity Research
Immune Design (IMDZ) reported narrower-than-expected loss and missed sales estimates in the third-quarter 2017.
Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q3
by Zacks Equity Research
Epizyme (EPZM) posted narrower-than-expected loss in the third quarter of 2017. It plans to meet the FDA to begin the registration strategy for its lead pipeline candidate, tazemetostat, in the next quarter.
Conatus (CNAT) Loss Wider Than Expected in Q3, Sales Miss
by Zacks Equity Research
Conatus (CNAT) reports wider-than-expected loss in Q3. However, revenues significantly increased year over year.
Novo Nordisk (NVO) Tops Q3 Earnings Estimates, Lags Sales
by Zacks Equity Research
Novo Nordisk A/S (NVO) reported third-quarter 2017 earnings of 63 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 58 cents. In fact, the reported figure was ahead of 57 cents earned a year ago.
Acorda (ACOR) Q3 Earnings Lag Estimates, Revenues Up Y/Y
by Zacks Equity Research
Acorda's (ACOR) performance in Q3 misses earnings and revenue estimates. However, the company's key drug Ampyra witnessed increase in sales year over year and inched up sequentially.
Dr. Reddy's (RDY) Q2 Earnings and Revenues Decline Y/Y
by Zacks Equity Research
Dr. Reddy's (RDY) earnings declined year over year but revenues increased on a year-over-year basis. The company remains focused on launching new products.
Novartis Buys French Radiopharmaceutical Company
by Zacks Equity Research
Novartis (NVS) plans to acquire France-based Advanced Accelerator Applications. The takeover will add RadioLigand Therapy, Lutathera, in its portfolio with potential to drive growth in the near term.